Canada markets closed

Cronos Group Inc. (CRON.TO)

Toronto - Toronto Real Time Price. Currency in CAD
Add to watchlist
3.88000.0000 (0.00%)
At close: 04:00PM EDT
Full screen
Previous Close3.8800
Open3.8400
Bid3.8900 x 0
Ask3.9000 x 0
Day's Range3.8400 - 4.0800
52 Week Range3.3200 - 8.4500
Volume171,626
Avg. Volume330,100
Market Cap1.466B
Beta (5Y Monthly)1.46
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Cronos Group Reports 2022 Second Quarter Results

    Consolidated net revenue increased by 48% year-over-year to $23.1 million in Q2 2022 Israel net revenue increased by 212% year-over-year to $7.2 million in Q2 2022 Announced achievement of THCV equity milestone TORONTO, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”), today announces its 2022 second quarter business results. “I am encouraged by the progress we are making to realign our business around our brands to become more efficient

  • GlobeNewswire

    Cronos Group Inc. to Hold 2022 Second Quarter Earnings Conference Call on August 9, 2022

    TORONTO, July 13, 2022 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”) will hold its 2022 second quarter earnings conference call on Tuesday, August 9, 2022 at 8:30 a.m. ET. Cronos’ senior management team will discuss the Company’s financial results and will be available for questions from the investment community after prepared remarks. To attend the conference call or webcast, participants should register online at https://ir.thecronosgroup.com/even

  • GlobeNewswire

    Cronos Group Partners with Geocann to Leverage VESIsorb® Delivery Technology for Faster Absorption

    TORONTO, June 27, 2022 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”) is pleased to announce the launch of the first of what is expected to be a range of products, in partnership with Geocann, which will utilize the advanced VESIsorb® delivery system. This technology provides better bioavailability and faster absorption. VESIsorb® formulations have set the industry benchmark in peer-reviewed published studies, delivering superior pharmacokinetic perf